EA029831B1 - Пептид, индуцирующий цитотоксические т-лимфоциты и стимулирующий антиопухолевые иммунные ответы - Google Patents

Пептид, индуцирующий цитотоксические т-лимфоциты и стимулирующий антиопухолевые иммунные ответы Download PDF

Info

Publication number
EA029831B1
EA029831B1 EA201000209A EA201000209A EA029831B1 EA 029831 B1 EA029831 B1 EA 029831B1 EA 201000209 A EA201000209 A EA 201000209A EA 201000209 A EA201000209 A EA 201000209A EA 029831 B1 EA029831 B1 EA 029831B1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumor
peptide
cells
peptides
cell
Prior art date
Application number
EA201000209A
Other languages
English (en)
Russian (ru)
Other versions
EA201000209A1 (ru
Inventor
Оливер Шор
Норберт Хильф
Тони Вайншенк
Клаудиа Траутвайн
Штеффен Вальтер
Харпрет Сингх
Original Assignee
Имматикс Байотекнолоджиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08005889.4A external-priority patent/EP2105501B1/en
Application filed by Имматикс Байотекнолоджиз Гмбх filed Critical Имматикс Байотекнолоджиз Гмбх
Publication of EA201000209A1 publication Critical patent/EA201000209A1/ru
Publication of EA029831B1 publication Critical patent/EA029831B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/02—Sulfotransferases (2.8.2)
    • C12Y208/02011—Galactosylceramide sulfotransferase (2.8.2.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201000209A 2007-07-27 2008-07-25 Пептид, индуцирующий цитотоксические т-лимфоциты и стимулирующий антиопухолевые иммунные ответы EA029831B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07014797 2007-07-27
US95316107P 2007-07-31 2007-07-31
EP08005889.4A EP2105501B1 (en) 2008-03-27 2008-03-27 Novel immunotherapy against neuronal and brain tumors
PCT/EP2008/006154 WO2009015843A1 (en) 2007-07-27 2008-07-25 Novel immunotherapy against neuronal and brain tumors

Publications (2)

Publication Number Publication Date
EA201000209A1 EA201000209A1 (ru) 2011-02-28
EA029831B1 true EA029831B1 (ru) 2018-05-31

Family

ID=39720257

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201000209A EA029831B1 (ru) 2007-07-27 2008-07-25 Пептид, индуцирующий цитотоксические т-лимфоциты и стимулирующий антиопухолевые иммунные ответы
EA201791519A EA034800B1 (ru) 2007-07-27 2008-07-25 Пептид, связывающийся с мнс-i, индуцирующий цтл и стимулирующий антиопухолевые иммунные ответы

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201791519A EA034800B1 (ru) 2007-07-27 2008-07-25 Пептид, связывающийся с мнс-i, индуцирующий цтл и стимулирующий антиопухолевые иммунные ответы

Country Status (21)

Country Link
US (6) US9175040B2 (enExample)
EP (2) EP2183361B1 (enExample)
JP (2) JP6008461B2 (enExample)
KR (2) KR101317989B1 (enExample)
CN (2) CN103911358B (enExample)
AU (1) AU2008281015B2 (enExample)
BR (1) BRPI0813621A2 (enExample)
CA (2) CA2694808C (enExample)
CY (1) CY1117115T1 (enExample)
DK (2) DK2183361T3 (enExample)
EA (2) EA029831B1 (enExample)
ES (2) ES2543815T3 (enExample)
HR (2) HRP20150820T1 (enExample)
HU (1) HUE027524T2 (enExample)
MX (1) MX2010001086A (enExample)
NZ (2) NZ592261A (enExample)
PL (2) PL2660248T3 (enExample)
PT (2) PT2183361E (enExample)
RS (2) RS54204B1 (enExample)
SI (2) SI2660248T1 (enExample)
WO (1) WO2009015843A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CN103911358B (zh) * 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8603485B2 (en) * 2011-01-05 2013-12-10 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
TWI755158B (zh) 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3919507A3 (en) 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) * 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
IL292864A (en) * 2015-08-28 2022-07-01 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
RS65430B1 (sr) 2016-03-16 2024-05-31 Amal Therapeutics Sa Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini
US20190167722A1 (en) * 2016-08-02 2019-06-06 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
MA49122A (fr) * 2017-04-10 2021-03-24 Immatics Biotechnologies Gmbh Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
PH12021553042A1 (en) 2019-06-06 2023-09-11 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
EP4110354A4 (en) * 2020-02-24 2024-11-13 The Regents of The University of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
WO2023049733A2 (en) * 2021-09-21 2023-03-30 The University Of Chicago Methods and composition using patient-derived autologous neoantigens for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075339A1 (en) * 1999-06-03 2000-12-14 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
US20020146370A1 (en) * 2001-03-23 2002-10-10 Agy Therapeutics Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
WO2005071059A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
WO2005116051A2 (de) * 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
NZ192465A (en) 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
JPS6081130A (ja) * 1983-10-07 1985-05-09 Fujisawa Pharmaceut Co Ltd 抗ｈｌａ−ａ２抗体およびそれを産生するハイブリド−マ
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5651972A (en) * 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5202666A (en) * 1991-01-18 1993-04-13 Net/Tech International Inc. Method and apparatus for enhancing hygiene
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0819171A1 (en) * 1995-04-07 1998-01-21 The Regents Of The University Of California Antibodies for the detection of hla-g
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE19739089A1 (de) * 1997-09-06 1999-03-11 Hella Kg Hueck & Co Scheinwerfer für Fahrzeuge
CA2304208A1 (en) * 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
JP2003012544A (ja) * 2001-03-27 2003-01-15 Kouji Egawa 癌予防・治療剤
US20050260132A1 (en) * 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
AU2002365187A1 (en) * 2001-11-07 2003-07-24 Mannkind Corporation Epitope synchronization in antigen presenting cells
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7236577B2 (en) * 2002-11-14 2007-06-26 International Business Machines Corporation Call screening system and method
KR100494979B1 (ko) * 2003-07-14 2005-06-14 주식회사 정우인터내셔날 조직 절편 보호 및 해상력 증진용 액상 커버 슬립, 그제조용 조성물, 그로부터 제조된 커버슬립을 구비한슬라이드 구조체 및 그 제조방법
US7050785B2 (en) * 2003-12-08 2006-05-23 Research In Motion Limited Apparatus and method of explicit indication of call from emergency call centre
US7315736B2 (en) * 2004-09-30 2008-01-01 Jenkins Nevin C Personal emergency communication system
US7231200B2 (en) * 2004-09-30 2007-06-12 Nevin Jenkins Personal emergency communication system
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
ES2330013T3 (es) 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
CN103911358B (zh) * 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
PL2113253T3 (pl) * 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075339A1 (en) * 1999-06-03 2000-12-14 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
US20020146370A1 (en) * 2001-03-23 2002-10-10 Agy Therapeutics Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
WO2005071059A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
WO2005116051A2 (de) * 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt "Ptprz1 protein (Fragment).", XP002484252 *
DATABASE UniProt "RecName: Full=Receptor-type tyrosine-protein phosphatase zeta; Short=R-PTP-zeta; EC=3.1.3.48; AltName: Full=R-PTP-zeta-2; AltName: Full=Protein-tyrosine phosphatase receptor type Z polypeptide 1; AltName: Full=Protein-tyrosine phosphatase receptor type Z polypeptide 2; Flags: Precursor;", XP002502066 *
MULHOLLAND PAUL J, ET AL: "Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme.", CELL CYCLE, TAYLOR & FRANCIS INC., US, vol. 5, no. 7, 1 April 2006 (2006-04-01), US, pages 783 - 791, XP002484251, ISSN: 1538-4101 *

Also Published As

Publication number Publication date
JP2010534464A (ja) 2010-11-11
ES2546610T3 (es) 2015-09-25
CN101809148B (zh) 2014-07-16
PL2183361T3 (pl) 2015-10-30
CA2863010A1 (en) 2009-02-05
US20160175357A1 (en) 2016-06-23
NZ592261A (en) 2012-09-28
AU2008281015A1 (en) 2009-02-05
JP5738348B2 (ja) 2015-06-24
KR20120025014A (ko) 2012-03-14
CN103911358A (zh) 2014-07-09
HK1191022A1 (en) 2014-08-29
EA034800B1 (ru) 2020-03-23
PL2660248T3 (pl) 2015-11-30
NZ582824A (en) 2012-07-27
EA201000209A1 (ru) 2011-02-28
EP2183361A1 (en) 2010-05-12
US20190321405A1 (en) 2019-10-24
EP2660248B1 (en) 2015-06-10
CA2863010C (en) 2017-01-24
AU2008281015A2 (en) 2010-05-27
BRPI0813621A2 (pt) 2017-05-09
US11648276B2 (en) 2023-05-16
US9175040B2 (en) 2015-11-03
HUE027524T2 (en) 2016-11-28
US10434120B2 (en) 2019-10-08
US20090123489A1 (en) 2009-05-14
CN101809148A (zh) 2010-08-18
CY1117115T1 (el) 2017-04-05
SI2183361T1 (sl) 2015-09-30
RS54147B1 (sr) 2015-12-31
MX2010001086A (es) 2010-04-09
SI2660248T1 (sl) 2015-10-30
EP2660248A1 (en) 2013-11-06
ES2543815T3 (es) 2015-08-24
WO2009015843A1 (en) 2009-02-05
KR101317989B1 (ko) 2013-10-14
US11986497B2 (en) 2024-05-21
CA2694808A1 (en) 2009-02-05
PT2183361E (pt) 2015-09-11
PT2660248E (pt) 2015-10-12
US20200345777A1 (en) 2020-11-05
US20230241111A1 (en) 2023-08-03
DK2183361T3 (en) 2015-07-27
RS54204B1 (sr) 2015-12-31
DK2660248T3 (en) 2015-09-07
KR20100040874A (ko) 2010-04-21
CA2694808C (en) 2015-10-13
CN103911358B (zh) 2017-03-01
EP2183361B1 (en) 2015-06-10
HRP20150820T1 (xx) 2015-09-11
HRP20150852T1 (hr) 2015-09-25
JP6008461B2 (ja) 2016-10-19
KR101290892B1 (ko) 2013-07-31
AU2008281015B2 (en) 2012-07-26
US10709735B2 (en) 2020-07-14
US20190076477A1 (en) 2019-03-14
JP2013226145A (ja) 2013-11-07
EA201791519A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
EA029831B1 (ru) Пептид, индуцирующий цитотоксические т-лимфоциты и стимулирующий антиопухолевые иммунные ответы
US20250145686A1 (en) Uterine cancer treatments
AU2021204201B2 (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
JP7205919B2 (ja) 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
TWI730306B (zh) 用於抗cll及其他癌症之免疫治療的新穎胜肽及胜肽組合物
CN107849107A (zh) 用于前列腺癌和其他癌症免疫治疗的新型肽和肽组合物
EA018456B1 (ru) Новые иммуногенные эпитопы для иммунотерапии
CN106459167A (zh) 急性骨髓性白血病(aml)等几种血液肿瘤的新型免疫疗法
TW201841937A (zh) 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
US12103984B2 (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CN111533799A (zh) 用于白血病和其他癌症免疫治疗的肽和肽组合物
Class et al. Patent application title: PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS Inventors: Juliane Sarah Walz (Tuebingen, DE) Daniel Johannes Kowalewski (Tuebingen, DE) Daniel Johannes Kowalewski (Tuebingen, DE) Markus Loeffler (Ammerbuch, DE) Moreno Di Marco (Tuebingen, DE) Nico Trautwein (Stuttgart, DE) Annika Nelde (Tuebingen, DE) Stefan Stevanovic (Tuebingen, DE) Stefan Stevanovic (Tuebingen, DE) Hans Georg Rammensee (Tuebingen, DE) Hans Georg Rammensee (Tuebingen, DE) Sebastian Haen (Tuebingen, DE)
TW202126676A (zh) 用於抗cll及其他癌症之免疫治療的新穎胜肽及胜肽組合物